13F Pro

SEC Form 4 reporting owner

Hansen Gwenn

Hansen Gwenn has filed 22 Form 4 transactions reported between January 30, 2026 and September 1, 2026, as Chief Scientific Officer of Nurix Therapeutics, Inc..

Name as filed: Hansen Gwenn

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$433K
7 lines
Companies
1
with Form 4 filings
Latest transaction
Sep 1, 2026
transaction date

Roles and reported holdings

  • NRIXNurix Therapeutics, Inc.
    Jan 30, 2026 – Sep 1, 2026

    Chief Scientific Officer

    Held directly117,227 sh as of Aug 4, 2026 · Form 4

    24 months: $433K sold

Transaction history

All 22 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 1, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct1,452$3K@ $1.86Form 4
Aug 5, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct4,356$8K@ $1.86Form 4
Aug 4, 2026NRIXChief Scientific OfficerOpen-market saleCode S · direct2,611$64K@ $24.64Form 4
Aug 4, 2026NRIXChief Scientific OfficerOpen-market saleCode S · direct1,500$36K@ $23.87Form 4
Jul 30, 2026NRIXChief Scientific OfficerOpen-market saleCode S · directAlso reported by Ring Christine3,847$90K@ $23.38Form 4
Jul 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct3,572—Form 4
Jul 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct2,858—Form 4
Jul 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct3,750—Form 4
Jun 25, 2026NRIXChief Scientific OfficerOpen-market saleCode S · direct5,394$108K@ $20.00Form 4
Apr 30, 2026NRIXChief Scientific OfficerOpen-market saleCode S · directAlso reported by Ring Christine3,214$53K@ $16.65Form 4
Apr 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct2,858—Form 4
Apr 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct3,750—Form 4
Apr 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct2,000—Form 4
Feb 10, 2026NRIXChief Scientific OfficerGrant or awardCode A · direct42,875—Form 4
Feb 10, 2026NRIXChief Scientific OfficerGrant or awardCode A · direct93,750—Form 4
Feb 3, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct31,333$26K@ $0.8400Form 4
Jan 30, 2026NRIXChief Scientific OfficerOpen-market saleCode S · direct98$2K@ $17.37Form 4
Jan 30, 2026NRIXChief Scientific OfficerOpen-market saleCode S · direct4,797$80K@ $16.58Form 4
Jan 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct2,859—Form 4
Jan 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct3,750—Form 4
Jan 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct2,000—Form 4
Jan 30, 2026NRIXChief Scientific OfficerOption exerciseCode M · direct3,207—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.